• Not Yet Enrolling

NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients

BOREALIS Trial - CMRG 010

NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients


CMRG 010-iberdomide-velcade-dex

Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients


This study will evaluate efficacy and tolerability of iberdomide, weekly bortezomib and dexamethasone administered in combination.


Sponsor:

Canadian Myeloma Research Group

 

ClinicalTrials.gov Identifier: NCT05272826


Official Title: A Single Arm, Multicentre, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial

First Posted: March 9, 2022


Click here for details on Clinicaltrials.gov

 

Drug: Iberdomide

Drug: Bortezomib

Drug: Dexamethasone

 






Posts Archive